Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 88 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $218 | -19.9% | 40 | 0.0% | 0.00% | – |
| Q2 2023 | $272 | – | 40 | 0.0% | 0.00% | – |
| Q1 2023 | $0 | – | 40 | -35.5% | 0.00% | – |
| Q4 2022 | $0 | -100.0% | 62 | -96.4% | 0.00% | – |
| Q3 2022 | $7,000 | -73.1% | 1,739 | +2.3% | 0.00% | – |
| Q2 2022 | $26,000 | +30.0% | 1,700 | 0.0% | 0.00% | – |
| Q1 2022 | $20,000 | -51.2% | 1,700 | +25.9% | 0.00% | – |
| Q1 2021 | $41,000 | -38.8% | 1,350 | 0.0% | 0.00% | – |
| Q4 2020 | $67,000 | +52.3% | 1,350 | +17.4% | 0.00% | – |
| Q3 2020 | $44,000 | – | 1,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |